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Background: VATS lobectomy is an established option for the treatment of early-stage NSCLC. 
Complete lymph node dissection (CD), systematic sampling (SS) or resecting a specific number of lymph 
nodes (LNs) and stations are possible intra-operative LN management strategies.
Methods: All VATS lobectomies from the “Italian VATS Group” prospective database were retrospectively 
reviewed. The type of surgical approach (CD or SS), number of LN resected (RN), the positive/resected LN 
ratio (LNR) and the number and types of positive LN stations were recorded. The rates of nodal upstaging 
were assessed based on different LN management strategies. 
Results: CD was the most frequent approach (72.3%). Nodal upstaging rates were 6.03% (N0-to-N1), 
5.45% (N0-to-N2), and 0.58% (N1-to-N2). There was no difference in N1 or N2 upstaging rates between 
CD and SS. The number of resected nodes was correlated with both N1 (OR =1.02; CI, 1.01–1.04; P=0.03) 
and N2 (OR =1.02; CI, 1.01–1.05; P=0.001) upstaging. Resecting 12 nodes had the best ability to predict 
upstaging (6 N1 LN or 7 N2 LN). The finding of two positive LN stations best predicted N2 upstaging [area 
under the curve (AUC) of receiver operating characteristic (ROC) =0.98].
Conclusions: Nodal upstaging (and, indirectly, the effectiveness of intra-operative nodal management) 
cannot be predicted based on the surgical technique (CD or SS). A quantitative assessment of intra-operative 
LN management may be a more appropriate and measurable approach to justify the extension of LN 
resection during VATS lobectomy. 
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Introduction
VATS lobectomy has recently gained acceptance as 
the ideal treatment for early stage non-small cell lung 
cancer (NSCLC) (1). The short- and long-term results 
are comparable or superior to those of open pulmonary 
lobectomy. Patients’ benefits include less pain, an earlier 
hospital discharge, and an improved ability to tolerate 
adjuvant treatments (2,3).
The overall and disease-free survival of patients 
undergoing lung resection is related to the final pathological 
nodal stage of disease. Provided an appropriate intra-
operative lymph node (LN) management, the absence of 
nodal metastases correlates with improved survival (4,5).
Different LN resection strategies have been suggested. 
Complete dissection of all hilar and mediastinal lymph-
nodes (CD) and systematic sampling (SS) of pre-
determinate nodal stations (SS) are the two most frequent 
approaches. CD refers to the removal of all the lymphatic 
and fatty tissue within specific anatomic landmarks; SS 
refers to the retrieval of one or more sample nodes from 
each identified station (6).
The interpretation of the role of both CD and SS may 
present a significant bias, considering that both techniques 
vary on the surgeon’s practice and are very difficult to define 
quantitatively. Therefore, it is difficult to measure the risk 
and benefits of one or the other strategy.
Other approaches for the evaluation of LN management 
during lung resection include the number of resected LN, 
the LN ratio (LNR), the number of resected LN stations, 
and nodal upstaging (7-11).
Nodal upstaging, defined as the finding of a higher N 
value on the final pathologic specimen compared to the pre-
operative clinical N, has been identified as a viable predictor 
of the adequacy of nodal management and, indirectly, as a 
surrogate for the identification of patients who are at risk of 
survival (12).
The possibility to perform an adequate LN resection 
during VATS lobectomy compared to open lobectomy has 
been extensively demonstrated (13-15).
Large, prospective, multi-institutional VATS lobectomy 
series from cancer databases may lack adequate information 
on intra-operative nodal management. More consistent and 
detailed data on intra-operative LN management may be 
available from retrospective, single center experiences, with 
the limitation of smaller datasets.
In January 2014, a multi-institutional collaborative 
project was initiated in Italy between accredited thoracic 
surgery programs, with the aim of prospectively collecting 
data from VATS lobectomy operations. Specific data on 
the management of LN during surgery was included in the 
database and has now become available for analysis.
The availability of a large bulk of detailed information on 
LN management during VATS lobectomy has prompted us 
to analyze the impact of different nodal resection strategies 
and to assess if one or more predictors of an adequate LN 
management could be identified in our population.
Methods
The Italian VATS Group registry database contains 
prospectively collected data on VATS lobectomies 
performed since January 1st, 2014 across 56 Italian certified 
thoracic surgery centers. All VATS lobectomies included 
in the database between 1/1/2014 and 10/21/2016 were 
considered for the analysis. Patients’ records included age, 
sex, Charlson and Eastern Cooperative Oncology Group 
(ECOG) comorbidity score (16,17), and the technique 
of VATS lobectomy. The pre-operative clinical stage was 
determined based on the results of pre-operative CT scan, 
PET scan, mediastinoscopy, and endoscopic bronchial 
or esophageal ultrasound (EBUS, EUS). The final post-
operative pathology report was available for all patients. 
The type of surgical technique used for the intra-operative 
management of hilar and mediastinal nodes was recorded 
(complete dissection or SS). Specific data on intra-operative 
LN management was also recorded, including the number 
of LN resected (RN), the number of positive LN, and the 
number and type of positive LN stations (LNS). A LNR 
(number of positive LN/number of LN resected) (LNR) 
was also calculated from the dataset.
The complication rates and early (30- and 90-day) 
survival were also analyzed. Complications were recorded 
according to the Dindo (18) classification and analyzed 
using a multivariate model to assess the impact of LN-
related variables.
Given the relatively short follow/up time, long-term 
overall and disease-free survival figures were not available 
yet for this population. Nodal upstaging was used as a 
predictor of the efficacy of intra-operative LN management 
and was the main outcome variable of the study. N0-to-N1, 
N0-to-N2, and N1-to-N2 upstaging was recorded and 
analyzed.
The aim of the study was to identify the intra-operative 
LN management strategy showing the best correlation with 
nodal upstaging. CD was compared with SS and with a 
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quantitative assessment of the number of LNR, LNS, type 
of positive stations and LNR. 
In order to summarize the most relevant features of the 
clinical variables, descriptive statistics were performed. 
Categorical variables are presented using the distribution 
of absolute frequencies (percentages and cumulative); 
continuous variables are presented as mean, standard 
deviation, median, max, min, and range. Data from the 
Italian VATS Group registry was retrieved using a specific 
query tool on 10/21/2016. The study was peer-reviewed 
and approved by the Italian VATS Group scientific 
advisory board. All the patients included in the prospective 
collection of data within the Italian VATS group study had 
signed an informed consent and the VATS group registry 
database project underwent approval by the IRRB of each 
participating center.
Continuous variables were reported as the mean ± 
standard deviation, whereas categorical variables were given 
as percentages. Fisher’s exact tests were used to compare 
dichotomous data, and Pearson’s χ2 for categorical variables. 
Proportional hazards assumptions were analytically assessed 
using Schoenfeld residuals. Violations were addressed by the 
inclusion of time-varying co-variable. Univariate Logistic 
Regression was performed to evaluate any association 
between dependent and independent variables. ROC 
analysis was performed to assess cut-off points that provided 
the best discriminating capacity for quantitative parameters. 
To overcome the over-dispersion caused by a Generalized 
Linear Model (GLM) with Poisson distribution we used 
a GLM with negative binomial distribution for LN count 
and for positive stations count. A fractional model was used 
for the N1 and N2 ratio variables. A two tailed P value 
below 0.05 was considered significant. Statistical analysis 
was performed using SAS 9.4 (SAS Institute Inc., Cary, NC, 
USA) and STATA package version 14 (STATA Corp LP, 
College, TX).
All the patients gave informed consent for participation 
to the study. The study was approved by the Ismett 
Institutional Research Review Board (IRRB) with the ID 
number IRRB/39/14.
Results
Within the above-mentioned time frame, 3,219 cases 
of VATS lobectomy were enrolled in the database. 58% 
of the patients were males and 42% were females. The 
mean age at the time of the operation was 67.6±9.02 years 
(range: 18–89 years). The average patient Charlson and 
ECOG comorbidity scores were 4.40±1.82 (range: 0–15) 
and 0.27±0.52 (range: 0–4), respectively. An “anterior” 
(biportal or triportal) surgical approach was used for VATS 
lobectomy in 85.38% of the cases. Other approaches 
(posterior, lateral, totally endoscopic, uniportal) were used 
in the remaining 14.62% of cases. An upper lobectomy was 
the most frequent operation performed (56.2% of all cases) 
and the right side was more frequently operated than the 
left (61.4% vs. 38.6% of the cases). Most of the cases had 
a diagnosis of adenocarcinoma (73.5%) or squamous cell 
carcinoma (15.3%) of the lung.
Ninety eight VATS lobectomies performed for benign 
disease and 233 vats lobectomies performed for malignant 
disease other than “non-small cell lung cancer” (NSCLC) 
were excluded from the analysis. Also, patients who 
underwent neo-adjuvant treatment (N=94) and patients who 
required conversion from VATS to thoracotomy (N=298) 
were excluded from the analysis, in order to avoid possible 
confounders.
Based on the pre-operative CT scan assessment, 
2,423 patients had early stage, clinical stage I or stage 
II NSCLC. 2,360 patients had a clinical evidence of N0 
disease (97.4%) while 63 had N1 disease (2.6%). A pre-
operative PET scan was available in 2,216 NSCLC patients 
(91.4%), while pre-operative invasive staging of the LN 
(mediastinoscopy, EBUS or EUS) was performed in 86 
patients (3.5%).
668 patients underwent intra-operative SS (27.7%) 
and 1743 complete dissection (72.3%) of all hilar and 
mediastinal LN. An average of 6.23±4.15 N1 LN (range: 
0–35) and 7.18±5.55 N2 LN (range: 0–49) were resected 
during surgery (Table 1). The average ratio of positive/
resected LN was 0.04 for N1 LN and 0.02 for N2 LN. 
The average number of positive LN stations was 1.63±0.98 
(range: 1–7): 1.22±0.45 N1 (range: 1–3) and 1.34±0.64 N2 
(range: 1–5).
Overall, nodal upstaging occurred in 292 (12.05%) 
patients. N0-to-N1 nodal upstaging occurred in 146 cases 
(6.03%), N0-to-N2 in 132 cases (5.45%). N1-to-N2 
upstaging was observed in 14 cases (0.58%) (Table 2).
Patients undergoing complete dissection had, in average, 
more N1 LN resected (6.56 vs. 5.38, P<0.001), but a similar 
N1 LNR (0.04 vs. 0.03; P=0.151) compared to patients 
undergoing SS.
Patients undergoing CD had also more N2 LN resected 
(7.93 vs. 5.24, P<0.001) and a slightly higher N2 LNR (0.03 
vs. 0.02; P=0.024) compared to patients undergoing SS.
The average number of positive LN stations was 1.68 in 
2064 Bertani et al. Lymph node management during VATS lobectomy
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2017;9(7):2061-2070jtd.amegroups.com
patients undergoing CD vs. 1.48 in patients undergoing SS 
(P=0.170). There was no statistically significant difference 
in the number of positive N1 and N2 retrieved LN stations 
between patients undergoing CD or SS (1.24 vs. 1.16 and 
1.37 vs. 1.21, respectively; P=0.634 and 0.523).
After univariate analysis, no difference could be 
appreciated in the rate of N0-to-N1 and N0-to-N2 
upstaging based solely on the type of surgical technique 
used for the intraoperative management of LN (CD or 
SS). The N0-to-N1 upstaging rate was 5.9% in patients 
undergoing CD vs. 6.4% in patients undergoing SS 
(P=0.627). The N0-to-N2 upstaging rate was 5.9% in 
patients undergoing CD vs. 4.2% in patients undergoing SS 
(P=0.086). N1-to-N2 upstaging was observed exclusively in 
patients undergoing CD (19 patients) (Table 2).
On logistic regression, the overall number of resected 
nodes was related with both N0-to-N1 (OR =1.02, 
CI, 1.01–1.04; P=0.03) and N0-to-N2 upstaging (OR 
=1.03; CI, 1.01–1.05; P=0.001) (Table 3). The ROC analysis 
showed that resection of 12 nodes was the best predictor of 
N1 upstaging with an Area under the curve (AUC) of ROC 
of 0.56 (N0-to-N2), while 11 nodes was the best predictor 
of N0-to-N2 upstaging with an AUC-ROC of 0.59.
The number of resected N1 nodes correlated with N0-
to-N1 upstaging (OR =1.07; CI, 1.04–1.11, P<0.001) but 
not with N0-to-N2 (OR =1.02; CI, 0.98–1.06; P=0.282) nor 
N1-to-N2 (OR =0.99; CI, 0.87–1.13; P=0.944) upstaging. 
Resection of 6 N1 nodes had the best discriminatory 
performance to predict N0-to-N1 upstaging, with an AUC-
ROC of 0.63.
The number of resected N2 nodes correlated with N0-
to-N2 (OR =1.05; CI, 1.02–1.07, p<0.001) and N1-to-N2 
upstaging (OR =1.07; CI, 1.02–1.14; P=0.008) but not with 
N0-to-N1 upstaging (OR =0.99; CI, 0.96–1.02; P=0.665). 
Resection of 7 N2 nodes had the best discriminatory 
performance to predict N0-to-N2 upstaging, with an AUC-
ROC of 0.60.
The number of positive nodal stations was correlated 
with N0-to-N1, N0-to-N2 and N1-to N2 upstaging, with 
an OR of 3.01, 13.81, and 3.57, respectively. The best 
discriminatory performance to predict N0-to-N1 upstaging 
was the finding of 1 positive LN node station (AUC-ROC 
=0.94). The best discriminatory performance to predict 
N0-to-N2 and N1-to-N2 upstaging was the finding of 
two positive LN stations (AUC-ROC =0.98 and 0.97, 
respectively, Figure 1).
The number of positive N1 LNS had also significant 
correlation with N0-to-N2 (OR = 6.83, AUC =0.75, T
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P<0.001) and N1-to-N2 (OR = 7.49, AUC =0.83, P<0.001).
An analysis of each single positive LN station resected 
was also performed to assess any potential relationship with 
nodal upstaging. Each single positive N1 station correlated 
well with N1 upstaging and each single positive N1 and N2 
stations correlated well with N2 upstaging. We were not 
able to find any role for one single LN station in predicting 
the rates of upstaging.
Interestingly, the preoperative T staging did not correlate 
with any upstaging. The final, pathologic T stage instead 
was a significant predictor of both N0-to-N1 (T2) and 
N0-to-N2 (T2-T3-T4) upstaging (Table 4).
To assess the influence of different pre-operative staging 
methods on the results of intraoperative LN management, 
Table 2 Rates of upstaging in patients undergoing complete dissection (CD) or systematic sampling (SS)
Type of lymph node dissection N Upstage (N0–N1) Upstage (N0–N2) Upstage (N1–N2)
Overall 2,411 146 (6.03%) 132 (5.45%) 14 (0.58%)
CD 1,743 (72.3%) 103 (5.9%) 104 (5.9%) 14 (0.80%)
SS 668 (27.7%) 43 (6.4%) 28 (4.2%) 0
CD vs. SS – P=0.627 P=0.086 P=0.020
Table 3 Impact on nodal upstaging of the number of lymph nodes, lymph node ratio and the number of positive nodal stations resected. 
Multivariate analysis
Upstage Overall # of resected LN # N1 resected LN # N2 resected LN N1 LN ratio N2 LN ratio Overall # of positive stations
N0–N1
OR 1.02 1.07 0.99 0.26 3.01
95% CI 1.01–1.04 1.04–1.11 0.96–1.02 0.03–2.44 2.53–3.58
AUC [N] 0.56 [12] 0.63 [6] 0.95 [0.07] 0.94 [1]
P value 0.037 <0.001 0.665 0.237 <0.001
N0–N2
OR 1.03 1.02 1.05 13.81
95% CI 1.01–1.05 0.98–1.06 1.02–1.07 10.2–18.7
AUC [N] 0.59 [11] 0.60 [7] 0.74 [0.06] 0.97 (0.07) 0.98 [2]
P value 0.001 0.282 <0.001 <0.001
N1–N2
OR 1.04 0.99 1.08 3.57
95% CI 0.99–1.09 0.87–1.13 1.02–1.14 2.58–4.93
AUC [N] 0.67 [13] 0.73 [7] 0.86 [0.08] 0.96 [0.08] 0.97 [2]
P value 0.064 0.944 0.008 <0.001
LN, lymph node; CD, complete dissection; SS, systematic sampling; OR, odds ratio; CI, confidence interval; AUC, area under the curve.
Figure 1 ROC analysis of the impact of the number of positive LN 
stations resected on N0-to-N2 upstaging. ROC, receiver operating 
characteristic; LN, lymph node.
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we applied the model of the study to the sub-population of 
patients who received both a pre-operative CT scan and 
PET scan (N=2,216). Both the overall and specific (N1 
or N2) upstaging rates were similar to the figures of the 
population who received staging with a CT scan only.
The occurrence of some complications after VATS 
lobectomy in some cases could be related to the modality 
of lymph-node management (Table 5). The number of 
resected LN correlated significantly with the occurrence 
of atrial fibrillation, pneumonia, chylothorax and phrenic 
nerve injury. Postoperative hemothorax was more frequent 
in patients with N0-to-N1 upstage, higher N1 LN rate, 
higher number of LN stations.
Discussion
The optimal intra-operative nodal management during 
lobectomy for early stage NSCLC has been debated for 
Table 4 Correlation between T staging and upstaging rates
T Stage N (%) N0 to N1 (%) N0 to N2 (%) N1 to N2 (%)
Preoperative T stage
T1 1,843 (76.1) 101 (5.5) 94 (5.1) 11 (0.6)
T2 536 (22.1) 41 (7.6); P=0.065 34 (6.3); P=0.263 3 (0.5); P=0.921
T3 43 (1.8) 3 (6.9); P=0.672 4 (9.3); P=0.228 0
Pathologic T stage
T1 1,514 (62.5) 77 (5.1) 53 (40.1) 6 (0.4)
T2 790 (32.6) 55 (6.9); P=0.07 64 (48.5); P<0.0001 6 (0.7); P=0.259
T3 105 (4.3) 13 (12.4); P=0.002 13 (9.8); P<0.0001 1 (0.9); P=0.416
T4 14 (0.6) 1 (7.1); P=0.729 2 (14.3); P=0.05 1 (7.1); P=0.08
Table 5 Type and occurrence of complications related to different LN management and lymph node-related variables during VATS lobectomy
Observed variable
Atrial fibrillation Pneumonia Hemothorax Chylothorax
Phrenic nerve 
injury
Laryngeal nerve 
palsy
I–II >II I–II >II I–II >II I–II >II I–II >II I–II >II
SS/CD 0.147 0.703 0.951 0.822 0.286 0.109
Upstage N0–N1 0.06 0.595 <0.001 0.859 0.670 0.757
Upstage N0–N2 0.756 0.159 0.408 0.201 0.684 0.100
Upstage N1–N2 0.569 0.790 0.0915 0.986 0.898 0.789
# LNR 0.035 0.470 0.037 0.466 0.963 0.453 0.095 0.036 0.028 N/A 0.992 N/A
# N1 LNR 0.080 0.413 0.834 0.656 0.864 0.785 0.621 0.033 0.080 N/A 0.318 N/A
N1 LNR 0.513 0.991 0.791 0.632 0.561 0.027 N/A N/A 0.579 N/A
# N2 LNR 0.081 0.692 0.005 0.469 0.845 0.194 0.009 0.094 0.051 N/A 0.463 N/A
N2 LNR 0.206 0.992 0.524 0.162 N/A N/A N/A 0.745 N/A
# Pos. LN station 0.545 0.992 0.656 0.170 0.987 0.247 0.929 0.995 N/A 0.047 N/A
# Pos. N1 LN station 0.367 0.981 0.364 0.749 0.988 0.005 N/A N/A 0.365 N/A
# Pos. N2 LN station 0.901 0.988 0.861 0.046 N/A 0.433 0.997 N/A 0.014 N/A
All values are presented as “P” and are significant for P values <0.05. LN, lymph node; LNR, lymph node ratio; N/A, not available. 
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decades. The importance of obtaining nodes for pathologic 
examination relies on the fact that the final pathologic N 
stage is strictly related to overall and disease-free survival.
Darling et al. explored the differences between CD 
and SS during lobectomy (6). The study suggested similar 
outcomes between the two approaches, and justified the 
use of SS as a less invasive but oncologically equivalent 
strategy for the intra-operative management of LN. In this 
study, including an intraoperative LN frozen section before 
randomization may have not reflected the standard clinical 
practice, as noted by Cerfolio (19).
Criticism to this type of analysis led to introducing more 
quantitatively reliable parameters for the assessment of LN 
resection during lobectomy.
Zhou and colleagues retrospectively reviewed the 
results of a single-center experience on 493 patients with 
early stage lung cancer undergoing VATS lobectomy or 
segmentectomy (20). They were able to show that sampling 
greater than 3 LN stations and greater than 10 LN was 
associated with an increase in nodal upstaging, and that 
sampling 3 or more LN stations was an independent 
predictor of mortality. These results suggest the feasibility 
of using a measurable intra-operative LN resection strategy. 
The study had the limitation of including both lobectomies 
and segmentectomies, of being a single-center series and of 
limiting the analysis to less than 500 patients.
Several authors have criticized a “quantitative” approach 
to the assessment of intraoperative LN management, mostly 
because of the inter-personal variability of the number 
of nodes. Riquet and colleagues (21) reviewed data from 
1,095 patients across two French centers and recognized a 
great variability of the number of nodes retrieved during 
lung resections, following a “Gaussian” distribution. They 
did not find any correlation between the number of resected 
nodes and patients’ outcome, and therefore strived the 
importance of resecting all the hilar and mediastinal nodal 
stations. The study included patients undergoing different 
types of lung resections, at all stages of disease.
Another pitfall of a quantitative assessment of LN 
resection is the variability of the pathologic evaluation of 
the number of nodes resected. Fragments of LN may be 
recorded as whole LN and the pathologist’s assessment may 
not be uniform across different institutions.
VATS has been recognized as an established surgical 
technique for the treatment of early stage lung cancer. The 
oncological outcomes of VATS lobectomy have been shown 
to be equal or superior to those of open lobectomy. The 
VATS approach has the advantage of less postoperative pain, 
faster post-operative patient recovery and discharge home, 
and a faster access to post-operative adjuvant treatments in 
case these are needed (2,3). Several studies have shown the 
feasibility and safety of an adequate LN resection using all 
VATS lobectomy techniques (13-15).
In Italy, in 2014, a large collaborative study on VATS 
lobectomy (“VATS Group”) was established and a 
prospective, multi-centric database was started. In our 
study, we identified a large population of patients with 
clinical early-stage NSCLC with a considerable amount of 
information on the management of LN, although lacking 
survival rates.
Most of the patients had a pre-operative CT scan and 
PET scan (90.7%). Only a minority of the patients had an 
invasive LN staging, either mediastinoscopy, EBUS or EUS. 
The availability of the PET scan for most patients with 
early-stage disease justify these findings. Also, the VATS 
Group recommends following the ESTS guidelines (22), 
suggesting invasive LN staging in tumors larger than 3 cm, 
centrally located or with positive PET findings. 
For most of the cases, the surgeon reported performing 
a complete nodal dissection (72.1%). This finding is also 
consistent with a broad acceptance and application of the 
European guidelines.
The average number of nodes retrieved during surgery 
matched those of other similar series in the literature: in 
average, 6.23 N1 and 7.18 N2 nodes were retrieved.
The nodal upstaging rate of 12.06% was slightly similar 
to the results of other studies. Licht et al. reported nodal 
upstaging in 11.9% of patients in their report from the 
Danish VATS lobectomy registry including 717 patients 
with stage I NSCLC (12). Boffa and colleagues reported an 
upstaging rate of 11.6% in a retrospective analysis of the 
STS database on 4,394 patients (14).
Our rates of nodal upstaging compare well with the rates 
reported from other large multicenter databases such as the 
National Cancer Database (12.8% for open lobectomies 
vs. 10.3 for VATS). Medbery and colleagues suggested that 
the lower upstaging rates observed for VATS cases might 
result from non-academic or non-research thoracic surgery 
divisions (23). Our database might be a source for further 
assessment of the relationship between surgeon’s experience 
and accuracy of lymphadenectomy, by using specific and 
dedicated tools.
The report of very low upstaging rates for VATS 
lobectomy (down to 4.8%), such as in the study by Martin 
et al. (24), who reviewed a state cancer database from 
Kentucky, might hold a significant selection bias and give an 
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altered perception of the role of VATS and on the adequacy 
of VATS lobectomy as a reliable oncologic procedure. 
Given the difficulty to collect adequate data on this topic, 
the relevance of the results obtained from a dedicated, 
multi-centric database such as the VATS Group registry 
should be further emphasized.
As expected, patients undergoing CD had a statistically 
significant higher number of LN resected compared to 
those undergoing SS, both N1 (6.61 vs. 5.38,) and N2 (7.93 
vs. 5.24). Nevertheless, this finding translated into an equal 
LNR for N1 nodes and only in a minimally higher LNR for 
N2 nodes. Similarly, the number of positive LNS was not 
statistically different between the CD and SS group.
The above findings are further supported by the fact 
that, in our series, the nodal upstaging rates were not 
significantly different between patients undergoing CD 
or SS, suggesting no evident benefit for one or the other 
approach. 
On the other side, we were able to correlate the rates 
of nodal upstaging to the number of LN resected (both 
N1 and N2). N1 and N2 upstaging were more frequent 
in patients who had 12 or more LN resected, as indicated 
by the ROC-AUC analysis. Resection of ≥6 N1 or ≥7 N2 
nodes was the threshold to obtain significant correlation 
with N0-to-N1 or N0-to-N2 upstaging, respectively. These 
figures strongly suggest that it may possible to discriminate 
between patients who will have nodal upstaging based 
on the number of resected LN, independently from the 
surgical technique. It is our expectation that, with the 
availability of more data, despite interpersonal variability, 
it may be eventually possible to set a minimum number of 
nodes to be resected to prevent inadequate staging.
Although our database lacked information about the 
number of LN stations resected, we had the opportunity 
to examine the number of positive LN stations resected. 
In general, the finding of at least one positive nodal station 
could predict N0-to-N1 upstaging, while the finding of 
at least two positive nodal stations was correlated to N0-
to-N2 upstaging (OR =3.01 and 13.8, P<0.0001). More 
interestingly, positive N1 nodal stations correlated with 
N0-to-N2 and N1-to-N2 upstaging. This may suggest that, 
during surgery, the presence of suspicious N1 nodes should 
mandate an aggressive N2 dissection in order to obtain an 
adequate nodal resection and staging.
We were interested in assessing if one specific positive 
LN station correlated with nodal upstaging, but this 
phenomenon was not observed in our series. Resecting one 
specific LN station cannot therefore be used as a viable tool 
to guide the intraoperative resection of LN.
Restricting the analysis to patients undergoing a more 
aggressive pre-operative staging didn’t change the figures 
of nodal upstaging. These findings suggest that CT/PET 
allows in most cases a reasonable pre-operative staging in a 
selected population of patients with stage I–II NSCLC.
The role of tumor size and location is also reported 
to play a significant role in the nodal upstaging rates in 
many papers comparing open and VATS lobectomy, as 
pointed out by Kocher et al. (25). In our VATS series, 
the proportion of T2 and T3 lesions was very small, as 
expected. Nevertheless, on logistic regression we could 
find a significant correlation between larger lesions and 
the N0-to-N1 (T3) and N0-to-N2 (T1, 2, 3) upstaging 
rates. This observation seems to justify the role of VATS 
lymph-node resections even for larger and centrally 
located lesions.
Some complications of VATS lobectomy could be related 
to specific approaches to lymph-node resection. While 
performing lymph-node dissection during lobectomy, the 
surgeon should be aware about the risk of complications such 
as atrial fibrillation, pneumonia, chylothorax, hemothorax 
and nerve injury. This study was not focused on the analysis 
of complications and further work is desirable on this topic.
As already mentioned, the study has some limitations. 
Due to the short follow-up period, survival rates were not 
yet available for this population. Nodal upstaging was used 
as a surrogate marker of the adequacy of intraoperative LN 
treatment and, indirectly, of the outcome of patients.
The possibility of sampling errors during the pathologic 
examination of the specimens may account for possible bias 
in assessing the number of nodes resected. Standardization 
or centralization of the pathology examination would 
improve the accuracy of the analysis.
In conclusion, we examined a large dataset of VATS 
lobectomies with specific data on intra-operative LN 
management. Our study compared the impact of different 
intraoperative approaches (CD/SS) to a more quantitative 
assessment of LN resected.
Performing CD or SS did not impact “per se” on the 
rates of nodal upstaging. Resecting a minimal number of 
nodes (12 overall or 6/7 for individual N1 or N2 levels) 
seems a promising approach to optimize the chances that 
nodal upstaging is not missed. Finding obviously pathologic 
LN stations during dissection should prompt at a more 
aggressive dissection due to the increased probability of 
upstaging. The availability of survival figures is needed to 
confirm the suggested findings.
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